文献速递淋巴瘤

罗米地辛联合环磷酰胺、多柔比星、长春新碱和泼尼松对比环磷酰胺、多柔比星、长春新碱和泼尼松治疗初治外周T细胞淋巴瘤患者:Ro-CHOP试验最终分析

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
PubMed 文献 · J Clin Oncol · 2024-02-16

Ro-CHOP III期随机对照试验最终分析显示,中位随访6年,罗米地辛联合CHOP(Ro-CHOP)组与CHOP组的中位无进展生存期分别为12.0个月和10.2个月(HR 0.79,95%CI 0.62-1.005,P=0.054),中位总生存期分别为62.2个月和43.8个月(HR 0.88,95%CI 0.68-1.14,P=0.324)。探索性分析中,中心reviewed的滤泡辅助T细胞淋巴瘤亚组Ro-CHOP组中位PFS显著更长(19.5 vs 10.6个月,HR 0.703,95%CI 0.502-0.985,P=0.039)。

要点

  • Ro-CHOP组与CHOP组的中位PFS分别为12.0个月和10.2个月,差异未达统计学显著(HR 0.79,P=0.054)。
  • Ro-CHOP组与CHOP组的中位OS分别为62.2个月和43.8个月,无显著差异(HR 0.88,P=0.324)。
  • 探索性分析中,滤泡辅助T细胞淋巴瘤亚组Ro-CHOP组中位PFS显著优于CHOP组(19.5 vs 10.6个月,HR 0.703,P=0.039)。

核心结论

  • 最终分析未显示罗米地辛联合CHOP较CHOP单药一线治疗外周T细胞淋巴瘤提高疗效。

研究设计与样本

  • Ro-CHOP III期随机对照试验(ClinicalTrials.gov标识符:NCT01796002),报告最后一名患者入组后5年的计划最终分析,中位随访6年。

主要发现

  • Ro-CHOP组与CHOP组的中位无进展生存期分别为12.0个月和10.2个月(HR 0.79,95%CI 0.62-1.005,P=0.054)。
  • Ro-CHOP组与CHOP组的中位总生存期分别为62.2个月和43.8个月(HR 0.88,95%CI 0.68-1.14,P=0.324)。
  • 探索性分析中,中心reviewed的滤泡辅助T细胞淋巴瘤亚组Ro-CHOP组中位PFS为19.5个月,CHOP组为10.6个月(HR 0.703,95%CI 0.502-0.985,P=0.039)。
  • 251例患者接受了二线治疗,复发或进展后的中位PFS2和OS2分别为3.3个月和11.5个月。
  • 在高度异质性的二线治疗中,未发现特定方案似乎提供更优的疾病控制;但维布妥昔单抗联合化疗观察到潜在获益(PFS的HR 0.431,95%CI 0.238-0.779,P=0.005),即使在排除间变性大细胞淋巴瘤亚型或在多变量模型中调整组织学和国际预后指数后仍存在。

关键数值与推荐

  • Ro-CHOP组与CHOP组的中位PFS分别为12.0个月和10.2个月(HR 0.79,95%CI 0.62-1.005,P=0.054)。
  • Ro-CHOP组与CHOP组的中位OS分别为62.2个月和43.8个月(HR 0.88,95%CI 0.68-1.14,P=0.324)。
  • 滤泡辅助T细胞淋巴瘤亚组Ro-CHOP组与CHOP组的中位PFS分别为19.5个月和10.6个月(HR 0.703,95%CI 0.502-0.985,P=0.039)。
  • 维布妥昔单抗联合化疗对比未联合方案的PFS HR为0.431(95%CI 0.238-0.779,P=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 二线治疗高度异质性,在此限制下未发现特定方案似乎提供更优的疾病控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary analysis of the Ro-CHOP phase III randomized controlled trial (ClinicalTrials.gov identifier: NCT01796002) established that romidepsin (Ro) plus cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) did not yield an increased efficacy compared with CHOP alone as first-line treatment of peripheral T-cell lymphoma. We report the planned final analysis 5 years after the last patient enrolled. With a median follow-up of 6 years, median progression-free survival (PFS) was 12.0 months compared with 10.2 months (hazard ratio [HR], 0.79 [95% CI, 0.62 to 1.005]; P = .054), while median overall survival was 62.2 months (35.7-86.6 months) and 43.8 months (30.1-70.2 months; HR, 0.88 [95% CI, 0.68 to 1.14]; P = .324) in the Ro-CHOP and CHOP arms, respectively. In an exploratory analysis, the median PFS in the centrally reviewed follicular helper T-cell lymphoma subgroup was significantly longer in the Ro-CHOP arm (19.5 v 10.6 months, HR, 0.703 [95% CI, 0.502 to 0.985]; P = .039). Second-line treatments were given to 251 patients with a median PFS2 and OS2 after relapse or progression of 3.3 months and 11.5 months, respectively. Within the limits of highly heterogeneous second-line treatments, no specific regimen seemed to provide superior disease control. However, a potential benefit was observed with brentuximab vedotin in association with chemotherapy even after excluding anaplastic large-cell lymphoma subtype or after adjusting for histology and international prognostic index in a multivariate model (HR for PFS, 0.431 [95% CI, 0.238 to 0.779]; P = .005).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Camus V, Thieblemont C, Gaulard P, et al. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. J Clin Oncol. 2024. PMID: 38364196. doi:10.1200/JCO.23.01687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。